Menu

Close

Sign InSign Out
ProductsOrderOrderSee allCo-pay cards & patient savings offersMaterialsSamples*Hospital products*Vaccines, biologics & small-molecule medicines**​​​​​​​​​​​​​​​​​​​​​Patient AssistancePatient AssistanceFind available assistance programsGo to Patient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore contentExplore contentExplore more contentEventsVideosMaterialsContactContactSee all contactPfizer corporateAsk a question

Menu

Close

AboutAboutBurden of IPDDosingDosingDosingAdministration and implementationEfficacy & Safety​​​​​​​Efficacy & SafetyEfficacySafety ProfileImmunogenicitySupport & Order​​​​​​​ Support & OrderVideosMaterialsOrder Prevnar 13®AdherenceResources

Administration and implementation

  • Shake vigorously prior to use to obtain a homogenous, white suspension in the vaccine container
  • Do not use the vaccine if it cannot be suspended or if particulate matter or discoloration is found
  • For intramuscular use only
  • ​​​​​​​The preferred sites for injection are the anterolateral aspect of the thigh in infants and the deltoid muscle of the upper arm in toddlers and children. Do not inject in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel
  • After being shipped, Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) may arrive at temperatures between 2°C and 25°C (36°F and 77°F)
  • Store refrigerated at 2°C to 8°C (36°F to 46°F)
  • Prevnar 13® is stable at temperatures up to 25°C (77°F) for 4 days. These data are not recommendations for shipping or storage, but may guide decisions for use in case of temporary temperature excursions
  • ​​​Do not freeze (discard if vaccine has been frozen)

CDC=Centers for Disease Control and Prevention.

Dosing

  • Dosing
  • Administration and implementation

Dosing

Review the CDC-recommended dosing schedule for Prevnar 13®

View now

Order from Pfizer Prime

To stock Prevnar 13®, call 1-800-666-7248 or click here

Order now

Register for PfizerPro

Support and services from Pfizer geared toward healthcare providers

Register now

PREVNAR 13 is a registered trademark of Wyeth LLC.
Manufactured by Wyeth Pharmaceuticals Inc.
© 2021 Pfizer Inc.
  • Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status, and the potential benefits and risks
  • In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
  • In children 6 weeks through 17 years, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
  • In children 6 years through 17 years of age, Prevnar 13® is administered as a single dose

Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). ​​Visit www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for Prevnar 13®.

  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
  • In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)​​​​​​​

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine

IndicationS

  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F​​​​​​​​​​​​​​
  • In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)
    ​​​​​​​

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine